Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands

Fig. 1

Decision analytic model to compare the health-economic outcomes of treating ER-positive/HER2-negative stage II-III breast cancer patients with response-guided NACT vs. conventional-NACT. Decision nodes (■); patient or health provider makes a choice. Chance nodes (●); more than one event is possible but is not decided by neither the patient or health provider. Abbreviations: NACT = neoadjuvant chemotherapy; RFS = relapse free survival; DFS = disease free survival; R = relapse; D = death; AC = cyclophosphamide, doxorubicine; DC = docetaxel, capecitabine

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us

\